1Thompson D, Pepys MB, SP.The physiological structure of human C-reactive protein and its complex with phosphocholine[J]. Structure Fold Des, 1999, 7(2) : 169.
2Lareway CA, Travese P, Walpost M, et al. Immunobiology : the immune system in health and disease[M] .4 th ed. USE:Gasland Publishing, 1999. 384 - 384.
3Togevik H, Claison L, Andersson R, et al. C-reactive protein is more sensitive than erythrocyte sedimentation rate for diagnosis of infective endocarditis[J]. Infection, 1997, 25(2) :82.
4Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women[J] . N Engl J Med, 2000, 342(12) : 836.
5Grundy SM,Bazzarre T, cleeman J, et al. Prevention conference V: beyond secondary prevention., identifying the high-risk patient for primary prevention[J]. Circulation,2000,101 :e3-e11.
6Roberts WL, Mouton L,Law TC, et al. Evluation of nine anomated high sensitivity C-reactive protein methods : implications for clinical and epidemiological applications[J].Clin Chem,2001,47:418-423.
7Vicky A Legrys. The use of high sensitiveity c-reactive protein in assessing the risk for coronary heart disease[J]. Clin Lab Sci, 2001,14(4) :243-246.
8Morrow DA,Ridker PM. C-reactive protein,inflammation and coronary risk[J]. Med Clin North Am,2000,84:149-161.
9Mublestein JB, Horne BD,Carlquist JF, et al. Cytomegalovirus seropositivity and C-reactive protein have independent and combined predictive value for mortality in patients with angiographically demonstrated coronary artery disease[J]. Circulation, 2000,102 : 1917-1923.
10Cavusoglu Y,Gorenek B,Alpsoy S, et al. Evaluation of Creactive protein, fibrinogen and antithrombin-2 as risk factor for coronary artery disease[J]. Isr Med Assoe J,2001,3:13-16.
